Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Growth 2024-2030

Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Growth 2024-2030

Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.



The global Age-Related Macular Degeneration (AMD) Treatment Drugs market size is projected to grow from US$ 10480 million in 2024 to US$ 14800 million in 2030; it is expected to grow at a CAGR of 5.9% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Forecast” looks at past sales and reviews total world Age-Related Macular Degeneration (AMD) Treatment Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Age-Related Macular Degeneration (AMD) Treatment Drugs sales for 2024 through 2030. With Age-Related Macular Degeneration (AMD) Treatment Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Age-Related Macular Degeneration (AMD) Treatment Drugs industry.

This Insight Report provides a comprehensive analysis of the global Age-Related Macular Degeneration (AMD) Treatment Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Age-Related Macular Degeneration (AMD) Treatment Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Age-Related Macular Degeneration (AMD) Treatment Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Age-Related Macular Degeneration (AMD) Treatment Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Age-Related Macular Degeneration (AMD) Treatment Drugs.

The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.

This report presents a comprehensive overview, market shares, and growth opportunities of Age-Related Macular Degeneration (AMD) Treatment Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Aflibercept
Ranibizumab
Others

Segmentation by Application:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Ionis Pharmaceuticals, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Biogen
Novartis AG
Sanofi S.A.
Bayer AG
Coherus Biosciences Inc
F. Hoffmann-La Roche Ltd
Apellis Pharmaceuticals Inc
AbbVie
Pfizer Inc.
Amgen Inc.
Samsung Bioepis

Key Questions Addressed in this Report

What is the 10-year outlook for the global Age-Related Macular Degeneration (AMD) Treatment Drugs market?

What factors are driving Age-Related Macular Degeneration (AMD) Treatment Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Age-Related Macular Degeneration (AMD) Treatment Drugs market opportunities vary by end market size?

How does Age-Related Macular Degeneration (AMD) Treatment Drugs break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.